CHALLENGES IN REGULATING QUALITY AND RATIONAL USE OF ANTIBIOTICS - PowerPoint PPT Presentation

1 / 18
About This Presentation
Title:

CHALLENGES IN REGULATING QUALITY AND RATIONAL USE OF ANTIBIOTICS

Description:

challenges in regulating quality and rational use of antibiotics alliance for the prudent use of antibiotics: inagural meeting courtyard hotel – PowerPoint PPT presentation

Number of Views:221
Avg rating:3.0/5.0
Slides: 19
Provided by: Hii7
Category:

less

Transcript and Presenter's Notes

Title: CHALLENGES IN REGULATING QUALITY AND RATIONAL USE OF ANTIBIOTICS


1
CHALLENGES IN REGULATING QUALITY AND RATIONAL USE
OF ANTIBIOTICS
  • ALLIANCE FOR THE PRUDENT USE OF ANTIBIOTICS
  • INAGURAL MEETING
  • COURTYARD HOTEL
  • 13th NOVEMBER 2007
  • M. Ndomondo-Sigonda
  • Director General - TFDA

2
Scope
  • About TFDA
  • Its Mission and Vision
  • Its Functions as MRA
  • Challenges

3
TFDA
  • Statutory organization under the MoH responsible
    for regulating and ensuring quality, safety
    efficacy of food, drugs (human, veterinary and
    herbal), medical devices cosmetic products
  • Established by the Act of parliament - Tanzania
    Food, Drugs Cosmetics Act, No.1, 2003
  • Followed repeal of Pharmaceuticals Poisons Act,
    1978 and Food (Control of Quality) Act, 1988

4
Its Mission Vision
  • Mission - To protect and promote public health by
    ensuring quality, safety and effectiveness of
    food, drugs, cosmetics and medical devices
  • Vision - To become the best authority in
    regulating food, drugs, cosmetics, and medical
    devices in Africa by 2015

5
Key Functions of TFDA as Medicines Regulatory
Authority
  • Regulation of drugs including antibiotics
    encompasses a variety of functions.
  • Amongst them include
  • Product evaluation registration
  • Licensing Inspection of manufacturing
    facilities distribution channels
  • Inspection and surveillance
  • Quality Control (QC)
  • ADR monitoring
  • Control of drug promotion advertising

6
1. Product Evaluation Registration
  • Also known as marketing authorization and product
    licensing
  • Carried out to ensure that a pharmaceutical
    product has been adequately evaluated for safety,
    efficacy quality and that the product
    information provided by the manufacturer is
    accurate.
  • Involves evaluation of technical administrative
    data submitted about a drug product, deciding
    whether to approve or reject the product and
    issuing a Registration Certificate

7
1. Product Evaluation
  • The overall process requires a legal foundation,
    an adequate number of qualified staff,
    sustainable resources, a data retrieval system
    and a system to ensure freedom from conflicts of
    interest, accountability and transparency.

8
2. Licensing of manufacturing, distribution
retail sale
  • Specifications regarding pharmaceutical premises,
    personnel and procedures must be followed by
    pharmaceutical manufacturers, distributors and
    retailers if they wish to obtain and retain their
    licence to operate.
  • By means of these licences, TFDA control the
    activities of pharmaceutical manufacturers,
    importers and distributors companies engaged in
    drug promotion and advertising.

9
3. Inspection Surveillance
  • Enables TFDA to monitor whether pharmaceutical
    operations are carried out in accordance with
    approved standards and guidelines.
  • In so doing, TFDA uncover weaknesses and actual
    errors in drug production, QC, storage
    distribution of drugs.
  • Activities include physical inspection and
    quality-testing of product samples.

10
4. Quality Control
  • Controlling the quality of drugs before and after
    registration has been issued, is critical for
    ensuring the quality and safety of drugs.
  • Access to a QC laboratory is of paramount
    importance
  • The capacity of a MRA to undertake quality
    surveillance is also directly related to the
    operational capability of the QC laboratory.
  • The results of a laboratory assessment of samples
    of marketed drugs permit the MRA to evaluate the
    actual quality of products used in the country
    and to identify problems pertaining to drug
    quality.

11
4. QC.
  • QC testing minimizes the amount of sub-standard
    drugs raw materials in circulation.
  • Encourage improvements in the standard of local
    manufacturing - manufacturers may be encouraged
    to upgrade their production sites, for example,
    by the prospect of an independent assessment of
    the quality of their products.
  • TFDA has a laboratory which operates to ensure
    that all of the above are being undertaken

12
5. ADR Monitoring (Pharmacovigilance)
  • Overseeing and monitoring adverse reactions to
    drugs are important mechanisms for assessing the
    safety and efficacy of pharmaceutical products.
  • ADR monitoring is an essential form of
    post-marketing surveillance for drugs already on
    the market.
  • The existence and operation of this system is
    important in drug regulation and reflect the
    Authoritys ability to regulate the entire
    process of pharmaceutical product assessment.

13
6. Control of Drug Promotion Advertising
  • Pharmaceutical manufacturers suppliers promote
    and/or advertise their products to health
    professionals the general public using a number
    of methods.
  • Advertising in journals or other media
  • Direct mailings
  • Personal selling through sales representatives
  • Provision of gifts and samples
  • Sponsored symposiums and sponsored publication of
    information materials

14
6. Drug Promotion Control.
  • Such promotion aims to influence peoples
    attitudes, beliefs behaviour and encourage them
    to use a particular brand of product.
  • Drug information can significantly influence the
    way drugs are used by consumers and providers of
    medicines (prescribers and dispensers).
  • Regulation of drug information and promotion is
    therefore necessary to prevent the dissemination
    of inaccurate and misleading information.

15
Challenges
  • Evaluation registration of drugs including
    antibiotics in terms of the number of qualified
    staff, available reference materials, data
    management and processing of drug applications
  • Licensing of premises taking into account again
    human resources available, size of the country
  • Inspection availability of financial human
    resources follow-ups after inspection
  • Quality testing equipment, reagents, analysts
    etc

16
Challenges..
  • Post-marketing surveillance (PMS) Collection of
    samples, screening, analysis results
    dissemination. TFDA has recently prepared a PMS
    programme which defines implementation strategies
    for efficient effective PMS.
  • ADR monitoring detecting, understanding, and
    assessing ADRs and sharing of information with
    the public
  • Promotion control follow-ups after approval or
    rejection, control of banners, control of
    misleading claims

17
Challenges..
  • Control of antibiotic resistance
  • Enforcement or control of antibiotic prescribing
    and dispensing practices including limiting as
    prescription only medicines (POM)
  • Monitoring of antibiotic resistance including
    dosage compliance and usage in food producing
    animals
  • Educating the public on the use of antibiotics

18
Ahsante
Write a Comment
User Comments (0)
About PowerShow.com